TP53 and neoplasm: For example, the Shi team conducted WGS on organoids derived from 84 pancreatic cancer patients and found that the organoids retained unique genomic characteristics associated with tumor molecular subtypes.[214] They identified key mutations, such as KRAS, TP53, and SMAD4, validating that the organoids accurately reflected the genetic traits of tumors.